Research advances in drug resistance markers in non-small cell lung cancer / 中国癌症杂志

ABSTRACT

Chemotherapy is the basic therapy in non small cell lung cancer, but combined chemotherapy has a response rate that still remains in the range of 30%-40%. Resistance of cancer cells to the anti tumor drugs is the main factor that reduces the efficacy of the chemotherapy. The mechanism of the drug resistance of lung cancer cells is very complex involving changes of drug resistance gene MDR1, MRP, LRP,GST, change of quality and quantity of toposomerase Ⅱ, ? tubulin gene mutation and fibroblast growth factor. Prospective measurement of the molecular marker as a guide for clinical chemotherapy is a key factor that can facilitate the individualization of the regime and thus increase the response rate.